Lumida
/EDIT
⌘K
Editas Medicine Inc

Editas Medicine Inc

EDIT
$2.70USD+1.89%+0.05 today

MARKET CAP

414.7M

P/E (TTM)

FWD P/E

DAY RANGE

$3 – $3

52W RANGE

$2
$5

AI Summary

Stalk
StalkMedium

While the asset remains in a Stage 4 decline with a decisive support failure and lower-high/lower-low regime, mean-reversion conditions are present as near‐low forward P/E, elevated FCF yield, and price at a prior defended zone signal a potential counter‐trend opportunity. Short-term price is extended below declining EMAs without clear exhaustion, suggesting deferred entry. Execution should focus on stalking shallow pullbacks into the 9 EMA, 21 EMA, or the area just above the 200 DMA to participate in an anticipated mean-reversion.

  • Renicel Ruby trial: all patients free from vaso-occlusive events post-infusion.
  • Q2 2024 cash of $318M funds operations and R&D into 2026.
  • Q1 2024 revenue dropped to $1.1M versus $9.9M in Q1 2023.
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$25.5M$19.7M$78.1M$32.3M$40.5M
YoY %-71.8%-22.8%+296.3%-58.6%+25.4%
P / Sales70.3x29.4x9.7x3.2x4.5x
EV / Sales67.2x30.0x10.0x5.6x4.8x
Gross Profit, Adj.$25.5M$19.7M$78.1M$32.3M$40.5M
YoY %-71.8%-22.8%+296.3%-58.6%+25.4%
Margin %100.0%100.0%100.0%100.0%100.0%
EV / Gross Profit67.2x30.0x10.0x5.6x4.8x
EBITDA, Adj.$-188.1M$-219.6M$-163.1M$-233.1M$-94.1M
YoY %-43.7%-16.8%+25.7%-42.9%+59.7%
Margin %-736.3%-1114.1%-208.8%-721.4%-232.1%
EV / EBITDA-9.1x-2.7x-4.8x-0.8x-2.1x
EBIT$-193.1M$-225.9M$-169.2M$-251.2M$-160.0M
YoY %-43.2%-17.0%+25.1%-48.5%+36.3%
Margin %-756.1%-1146.3%-216.6%-777.2%-394.9%
EV / EBIT-8.9x-2.6x-4.6x-0.7x-1.2x
Net Income$-192.5M$-220.4M$-153.2M$-237.1M$-160.1M
YoY %-66.0%-14.5%+30.5%-54.7%+32.5%
Net Margin-753.6%-1118.3%-196.1%-733.7%-395.0%
EPS (GAAP)-$2.85-$3.21-$2.02-$2.88-$1.80
YoY %-43.9%-12.6%+37.1%-42.6%+37.5%